Xenon Pharmaceuticals Inc. - Common Shares (XENE)

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine franchise by Pfizer Inc. (NYSE: PFE) in 2022, the "new" Biohaven—often called Biohaven 2.0—is grappling with the harsh realities of clinical-stage drug development. The [...]

As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their forecasts for 2026, projecting a staggering $5.1 trillion in total deal volume—a figure that would eclipse the previous records of

The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of mega-cap technology titans, investors are aggressively reallocating capital into the small-cap sector, propelling the Russell 2000 Index

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear.

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Soleno just turned profitable for the first time—right as a major fund made its move.

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.